myotonic dystrophy type 1 is the commonest neuromuscular disease affecting adults. It is inherited in an autosomal dominant manner, and is linked to a dynamic expansion of a CTG triplet repeat localised to chromosome 19q13.3. The phenotype can be divided into four main groups: mild, juvenile, classical, and congenital. The most severe form of the condition is observed in congenitally affected infants usually born to classically affected mothers. Recently, the nomenclature has been revised and myotonic dystrophy is referred to as DM1.1

Congenital myotonic dystrophy (CDM) was first described in 19602 and is the most severe phenotypic expression of DM1. It represents the final stage in the typical three generation anticipation cascade observed in this condition.3 The symptoms may present late in pregnancy with reduced fetal movements, polyhydramnios, or hydrops fetalis.4-6 Often the birth of a severely affected child identifies an extensive DM1 pedigree. The reasons for the almost exclusive maternal transmission of CDM are not clearly understood. There are no particular clinical features in the mothers of CDM children to account for this, but, from earlier studies, all the women exhibited clinical myotonia4 and CDM cases were confined to the offspring of clinically affected women.7 Koch et al8 found that only women with multisystem signs of DM1 at the time of pregnancy and delivery were likely to have congenitally affected offspring and that the chance of having a more severely affected child increased with maternal disease severity. These observations have been given support by more recent molecular studies; infants with CDM and their mothers had greater amplification of the CTG repeat than those with non-CDM and their mothers9 and the maternal expansion was three times greater in the CDM group than in the non-CDM group.10 We present data to allow estimation of risk, based on maternal and fetal genotypes.

METHODS AND RESULTS

Full clinical information was obtained from DM1 pedigrees in Northern Ireland, the Basque area of Spain, and the Grampian region of Scotland. The patients were classified as classical (onset of clinical symptoms from 16 years or older), juvenile (onset of symptoms such as muscle weakness, learning difficulties, or myotonia between 1 and 16 years), and congenital (symptomatic from birth). Genomic DNA was isolated from peripheral blood leukocytes by standard procedures. Molecular genetic analysis of the CTG trinucleotide expansion associated with DM1 was performed. Polymerase chain reaction (PCR) was carried out using fluorescent primers and subsequent analysis on an automated sequencer with Genescanner software. Southern blotting was performed on samples showing a single sized allele. Digest was with BglII and hybridisation with probe pB1.411-12 or cDNA25 and pGB2.6.13 The expansion size was determined by the midpoint of the smear.

A total of 30 offspring had CDM (group 1), with expansion size ranging from 1.6 to 6.5 kb, mean 3.9 kb. There were no cases of paternally inherited CDM. The mothers of the CDM children had expansions ranging from 0.23 to 5 kb, mean 1.98 kb. Sixty-two offspring had either juvenile onset DM1 or classical DM1 (group 2). In this group, the expansion size ranged from 0.129 to 4 kb (mean 2.17 kb). Their mothers had expansions ranging from 0.12 to 3.5 kb, mean 0.71 kb. All sibships except two (from the Aberdeen group) showed exclusive CDM or DM1 phenotypes.

One of the CDM offspring showed a contraction in the DM1 mutation inherited from his mother. The contraction was just over 1 kb, from 3.83 kb to 2.73 kb. One stable transmission was seen where the mother had a large amplification of ~5 kb, as did her son. The mothers of CDM offspring have a DM1 expansion which is on average 1.27 kb greater than the expansion in mothers of the milder classical form. On transmission to their offspring, the expansion undergoes greater amplification in the CDM mothers, by approximately 0.56 kb (table 1). The distribution of transmitted expansions shows a much higher concentration of CDM once the maternal expansion exceeds 1 kb. Five stable transmissions (8%) and two contractions (3%) of 1 kb each were observed in the non-CDM offspring.

DISCUSSION

The neonatal period can be critical for CDM babies. If they establish respiratory and feeding successfully, muscular hypotonia improves.3,14 The highest risk of death is in the neonatal period. Harper7 reported a death rate of 66% for this stage. As CDM was only described as recently as 1960,7 the clinical phenotype of adult CDM patients is still evolving.

The sex of the affected grandparent in CDM sibships was male in 57 of the 69 sibships where the grandparental sex was known (82.6%). Our findings support those of previous studies,15,16 but only the study of Lopez de Munain et al15 included mutational analysis.

When classically affected women are divided into those who have CDM offspring and those who have non-CDM offspring, the more severely affected mothers of the CDM children transmit a larger increase in the mutation. Koch et al17 published genetic risks for children of women with myotonic dystrophy, but this was before the advent of direct mutational analysis. Our observations certainly support the findings of Koch et al,17 in that the risks are different for two groups of women. The mean expansion size in mothers of CDM offspring is almost twice that seen in the mothers of non-CDM offspring.

There are definite differences observed between mothers of CDM offspring and mothers of non-CDM offspring. The mothers of CDM offspring have smaller families, possibly

Abbreviations: DM1; myotonic dystrophy; CDM, congenital myotonic dystrophy
because their disease severity and earlier age of onset naturally limits fertility or because of reproductive choices after the birth of a CDM child.

Our results suggest that if her DM1 expansion is >1 kb, then her risk of a CDM child in the first affected pregnancy is 59%. If her expansion is ≤1 kb, the risk of a CDM child is 17% (table 2). However, the risk is almost 100% if there is a sib with CDM.

A DM1 mother in her first pregnancy is more likely to have a CDM child if: (1) she has multisystem clinical signs at the time of pregnancy; (2) her age of onset is less than 30 years; (3) her affected parent is her father; and (4) her DM1 expansion is >1 kb.

Segregation distortion in DM1 must also be considered, and would suggest that there may be preferential transmission of the DM1 allele, resulting in a greater than 50% risk of an affected child in any pregnancy. Further data will help refine these risks. It is also important to note that the DM1 repeat is somatically unstable, and there is a trend towards an increase in the DM1 expansion on transmission to CDM/non-CDM offspring.

### Table 1 Increase in the DM1 expansion on transmission to CDM/non-CDM offspring

<table>
<thead>
<tr>
<th>Maternal DM1 repeat size</th>
<th>Increase in repeat size on transmission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Classical onset DM1 mothers (n=30)</td>
<td>1.98 kb (0.23–5 kb)</td>
</tr>
<tr>
<td>Non-CDM offspring (n=62)</td>
<td>0.71 kb (0.12–3.5 kb)</td>
</tr>
<tr>
<td>1.88 kb (−1.1–5.1 kb)</td>
<td></td>
</tr>
<tr>
<td>1.32 kb (−1.0–3.775 kb)</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2 Risk of CDM with different cut offs of expansion size

<table>
<thead>
<tr>
<th>Maternal expansion cut off (kb)</th>
<th>Chance of child having CDM if expansion &gt; cut off (%)</th>
<th>Chance of a child having CDM if expansion ≤ cut off (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>49</td>
<td>16</td>
</tr>
<tr>
<td>1</td>
<td>59</td>
<td>17</td>
</tr>
<tr>
<td>2</td>
<td>71</td>
<td>24</td>
</tr>
<tr>
<td>3</td>
<td>75</td>
<td>29</td>
</tr>
<tr>
<td>4</td>
<td>100</td>
<td>31</td>
</tr>
</tbody>
</table>

**REFERENCES**


**Authors’ affiliations**

A C Magee, N C Nevin, Regional Genetics Service, A Floor, Belfast City Hospital Trust, Lisburn Road, Belfast BT9 7AB, Northern Ireland

A E Hughes, N C Nevin, Department of Medical Genetics, The Queen’s University of Belfast, Lisburn Road, Belfast BT9 7AB, Northern Ireland

A Kidd*, K Kelly, J Dean, Department of Medical Genetics, Medical School, Foresterhill, Aberdeen AB25 ZGD, UK

A Lopez de Munain, A M Cobo, Neurology and Clinical Epidemiology Departments, Hospital Ntra Sra Aranzazu, San Sebastian, Basque Country, Spain

*Present address: Central Regional Genetic Service, Wellington Hospital, Wellington South, New Zealand

Correspondence to: Dr A Magee, Regional Genetics Service, A Floor, Belfast City Hospital Trust, Lisburn Road, Belfast BT9 7AB, Northern Ireland, Alex.Magee@bch.n-i.nhs.uk